Avalyn Hits Enrollment Target in Phase 2b Trial for Progressive Pulmonary Fibrosis Therapy — Avalyn Pharma Inc.

Event summary

Avalyn Pharma completed target enrollment of 375 patients in the Phase 2b MIST trial for AP01 (inhaled pirfenidone) in progressive pulmonary fibrosis (PPF).
The trial is a global, randomized, double-blinded, placebo-controlled study evaluating two doses of AP01 against placebo.
Primary endpoint is change in lung function (FVC) at 52 weeks, with topline data expected in the second half of 2027.
AP01 is an optimized inhaled formulation of pirfenidone, designed to reduce systemic side effects compared to oral administration.

The big picture

Avalyn’s progress in the MIST trial underscores the urgent need for better treatments for progressive pulmonary fibrosis, a condition with poor prognosis and limited therapeutic options. The shift from oral to inhaled delivery of pirfenidone could represent a significant advancement in managing respiratory fibrosis, potentially improving patient compliance and outcomes. Success in this trial could position Avalyn as a key player in the respiratory disease space, competing with established oral antifibrotics.

What we're watching

Clinical Efficacy: Whether AP01 can demonstrate superior lung function preservation compared to placebo in the MIST trial.
Tolerability Profile: The extent to which AP01’s inhaled formulation reduces gastrointestinal and liver-related side effects observed with oral pirfenidone.
Regulatory Pathway: The pace at which Avalyn can advance AP01 toward potential approval if Phase 2b results are positive.